Human Anthrax: Update of the Diagnosis and Treatment
Diagnostics · 10.03.2023 · 13 (6) · 1056
DOI: 10.3390/diagnostics13061056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 10.03.2023. Verfasst von Mehmet Doganay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Faculty of Medicine, Lokman Hekim University, 06510 Ankara, Turkey. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anthrax is one of the most important zoonotic diseases which primarily infects herbivores and occasionally humans. The etiological agent is Bacillus anthracis which is a Gram-positive, aerobic, spore-forming, nonmotile, rod-shaped bacillus. The spores are resistant to environmental conditions and remain viable for a long time in contaminated soil, which is the main reservoir for wild and domestic mammals. Infections still occur in low-income countries where they cause suffering and economic hardship. Humans are infected by contact with ill or dead animals, contaminated animal products, directly exposed to the spores in the environment or spores released as a consequence of a bioterrorist event. Three classical clinical forms of the disease, cutaneous, gastrointestinal and inhalation, are seen, all of which can potentially lead to sepsis or meningitis. A new clinical form in drug users has been described recently and named “injectional anthrax” with high mortality (>33%). The symptoms of anthrax in the early stage mimics many diseases and as a consequence it is important to confirm the diagnosis using a bacterial culture or a molecular test. With regards to treatment, human isolates are generally susceptible to most antibiotics with penicillin G and amoxicillin as the first choice, and ciprofloxacin and doxycycline serving as alternatives. A combination of one or more antibiotics is suggested in systemic anthrax. Controlling anthrax in humans depends primarily on effective control of the disease in animals. Spore vaccines are used in veterinary service, and an acellular vaccine is available for humans but its use is limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Faculty of Medicine, Lokman Hekim University, 06510 Ankara, Turkey.
- Department of Medical Microbiology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey.
- Department of Molecular Microbiology, Genome and Stem Cell Center, Erciyes University, 38280 Kayseri, Turkey.
- Department of Infectious Diseases, International Higher School of Medicine, Bishkek 720010, Kyrgyzstan.
- School of Pharmacy and Pharmaceutical Science, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3NB, UK.
ORCID-Profile: Mehmet Doganay, Gokcen Dinc
Zitieren
APA
Doganay, M., Dinc, G., Kutmanova, A., & Baillie, L. (2023). Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics, 13(6), 1056. https://doi.org/10.3390/diagnostics13061056
Vancouver
Doganay M, Dinc G, Kutmanova A, Baillie L. Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics. 2023;13(6):1056. doi:10.3390/diagnostics13061056
BibTeX
@article{Doganay2023,
author = {Doganay, Mehmet and Dinc, Gokcen and Kutmanova, Ainura and Baillie, Les},
title = {Human Anthrax: Update of the Diagnosis and Treatment},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {6},
pages = {1056},
doi = {10.3390/diagnostics13061056}
}
EUVIMED